India prepares for massive COVID-19 vaccination drive 'Intense concerns' The All India Drug Action Network, a nonprofit health watchdog, said it was "shocked" to see approval for Covaxin, a vaccine candidate with a lack of peer-reviewed safety and efficacy data. "In light of the intense concerns arising from the absence of efficacy data and hence the limited regulatory review of the vaccine candidate, the implications of public rollout of an untested product, and lack of transparency, we urge the DCGI to reconsider the recommendations of the expert committee in granting the approval to Covaxin," it said. Virologists like Shahid Jameel, director of the Trivedi School of Biosciences at Ashoka University, said he was confused with the terminology used by the DCGI.